Evaluation of Oncoxin-Viusid® in Cutaneous Melanoma

Inclusion Criteria: * Patients with histological diagnosis of Malignant Cutaneous Melanoma in stage IIB-IIC-IIIA * Subjects of 18 years and over of both sexes. * General health status according to the Karnofsky Index ≥ 70. * Laboratory parameters within the normal limits defined as: Hematopoietic: Hemoglobin ≥ 9 g / L, Total Leukocytes ≥ 3 x 109 cells / L, Neutrophils ≥ 1.5 x 109 cells / L, Platelets ≥ 100 x 109 / L Hepatic: Liver function within 2.5 times upper normal limit and without liver disease demonstrated by TGP, OGT and alkaline phosphatase. * Patients who express written voluntariness to enter the study with their signature of the informed consent document. * Women of childbearing age should have a negative pregnancy test and use effective contraceptive methods such as intrauterine devices, hormonal contraceptives, barrier method or tubal ligation. Exclusion Criteria: * Pregnancy or lactation. * Patients with a second concomitant tumor. * Present an associated chronic disease in the decompensation phase (heart disease, diabetes, hypertension). * History of hypersensitivity to another similar product. * Severe acute allergic states. * Severe septic processes. * Non-operated patients, in whom the surgery was contraindicated. * Patients at potential risk of not completing the study (those who will travel during the period of the investigation or distance in their residence, outside the city). * Subjects who are participating in another clinical trial. * Patients with cognitive disorders or a mental disorder that hinders their follow-up.